BRANFORD, FL — Vision Diagnostics, Inc., DBA Validity Diagnostics (VDx), is a research-based developer and manufacturer of diagnostic products, announced Feb. 24 that the United States Patent and Trademark Office (USPTO) has issued two patents and VDx expects the issuance of two pending patents related to urine drug screen sample validity test panels.
The USPTO has issued U.S. Patent No. 11,214,821 titled, “Reagents and methods of use with automated analyzers for obtaining a specific gravity index for urine.” This patent covers utilizing reagents in automated laboratory equipment to determine whether the specific gravity of a urine sample is abnormal, as an indication of adulteration.
The USPTO has also issued U.S. Patent No. 10,571,457 titled, “Methods for the detection of oxidative adulterants in urine sample.” The patent covers methods of confirming the presence of an adulterant in a urine sample by using a reagent capable of reacting with uric acid and non-urate markers in a urine sample.
Patents for the detection of synthetic urine and substance use disorder (SUD) are pending and VDx expects issuance by April of this year.
About Specimen Validity Testing (SVT)
With drug use and the subversion of drug tests at an all-time high, VDx’s new SVT panel detects a multitude of subversion techniques such as adulteration. This reduces false negatives in medical laboratories and helps increase overall compliance, limiting the use of pharmaceutical drugs within the substance use disorder (SUD) patients.
“Two years ago, there were as many drug overdose deaths annually than deaths in the entire Vietnam War, and as of 2021, that number has doubled. Our data shows that 20 to 40 percent of drug screens are being subverted and it is as easy as an internet search for “pass my drug test,” says VDx CEO Robbie Suggs. “Accurate drug testing should start with verifying that the specimen hasn’t been adulterated or substituted, and the VDx panel does just that.”
– This press release was provided by Validity Diagnostics